MX2011001551A - Tratamiento para la perdida de la audicion. - Google Patents

Tratamiento para la perdida de la audicion.

Info

Publication number
MX2011001551A
MX2011001551A MX2011001551A MX2011001551A MX2011001551A MX 2011001551 A MX2011001551 A MX 2011001551A MX 2011001551 A MX2011001551 A MX 2011001551A MX 2011001551 A MX2011001551 A MX 2011001551A MX 2011001551 A MX2011001551 A MX 2011001551A
Authority
MX
Mexico
Prior art keywords
noise
adenosine
exposure
receptor agonist
administration
Prior art date
Application number
MX2011001551A
Other languages
English (en)
Spanish (es)
Inventor
Srdjan Vlajkovic
Peter Rowland Thorne
Gary David Housley
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Publication of MX2011001551A publication Critical patent/MX2011001551A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2011001551A 2008-08-11 2009-08-11 Tratamiento para la perdida de la audicion. MX2011001551A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ57046908 2008-08-11
PCT/NZ2009/000164 WO2010019057A1 (en) 2008-08-11 2009-08-11 The treatment of hearing loss

Publications (1)

Publication Number Publication Date
MX2011001551A true MX2011001551A (es) 2011-03-29

Family

ID=41669060

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011001551A MX2011001551A (es) 2008-08-11 2009-08-11 Tratamiento para la perdida de la audicion.

Country Status (8)

Country Link
US (1) US20110207689A1 (cg-RX-API-DMAC7.html)
EP (1) EP2328577A4 (cg-RX-API-DMAC7.html)
JP (1) JP2011530585A (cg-RX-API-DMAC7.html)
CN (1) CN102159209A (cg-RX-API-DMAC7.html)
AU (1) AU2009280369A1 (cg-RX-API-DMAC7.html)
CA (1) CA2733918A1 (cg-RX-API-DMAC7.html)
MX (1) MX2011001551A (cg-RX-API-DMAC7.html)
WO (1) WO2010019057A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6279496B2 (ja) * 2015-01-08 2018-02-14 積水化成品工業株式会社 発泡粒子及び発泡成形体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248770A (en) * 1984-10-26 1993-09-28 The United States Of America, As Represented By The Department Of Health And Human Services Molecular probes for adenosine receptors
US4968672A (en) * 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
SE9401499D0 (sv) * 1994-05-02 1994-05-02 Item Dev Ab New method of treatment
WO1997037667A1 (en) * 1996-04-10 1997-10-16 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of an a1 adenosine receptor agonist to treat cerebral ischaemia
US6649621B2 (en) * 1997-12-16 2003-11-18 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US6177434B1 (en) * 1997-12-16 2001-01-23 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
WO2004096256A1 (en) * 2001-01-23 2004-11-11 The United States Of America, As Represented By The Secretary Of The Navy Methods for preventing and treating loss of balance function due to oxidative stress
WO2009132050A2 (en) * 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions

Also Published As

Publication number Publication date
JP2011530585A (ja) 2011-12-22
CA2733918A1 (en) 2010-02-18
EP2328577A1 (en) 2011-06-08
WO2010019057A1 (en) 2010-02-18
EP2328577A4 (en) 2011-10-19
CN102159209A (zh) 2011-08-17
US20110207689A1 (en) 2011-08-25
AU2009280369A1 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
Pourbakht et al. Ebselen attenuates cochlear damage caused by acoustic trauma
US20210308120A1 (en) Use of Amitriptyline for Blocking Brain Hemichannels and Method for Potentiating its Effect in Vivo
Yamashita et al. Delayed production of free radicals following noise exposure
Shoji et al. Differential protective effects of neurotrophins in the attenuation of noise-induced hair cell loss
Himeno et al. Intra-cochlear administration of dexamethasone attenuates aminoglycoside ototoxicity in the guinea pig
KR101429735B1 (ko) 와우각 흥분독성에 의해 유발된 이명의 치료를 위한 nmda 수용체 길항제의 용도
JP6994765B2 (ja) 難聴の処置のためのセトロンファミリーのカルシニューリン阻害剤
JP2009510047A (ja) 蝸牛興奮毒性によって誘導される耳鳴りを処置する方法
CN110337291A (zh) 治疗耳蜗突触病变的方法
Wong et al. Post exposure administration of A1 adenosine receptor agonists attenuates noise-induced hearing loss
US20200188332A1 (en) Methods for the treatment of tinnitus induced by cochlear excitotoxicity
CA3136424A1 (en) Combination of chir99021 and valproic acid for treating hearing loss
Manalo et al. Adenosine A2B receptor: A pathogenic factor and a therapeutic target for sensorineural hearing loss
Kempfle et al. Experimental drugs for the prevention or treatment of sensorineural hearing loss
JP2015511242A (ja) 病変性前庭障害の治療に使用するカルシニューリン阻害剤
Bielefeld Protection from noise-induced hearing loss with Src inhibitors
US20110207689A1 (en) The treatment of hearing loss
Bielefeld et al. Protection from impulse noise-induced hearing loss with novel Src-protein tyrosine kinase inhibitors
US20070078177A1 (en) Methods and compositions for treating non age related hearing impairment in a subject
US20240294925A1 (en) Method of Treatment for Auditory Dysfunction
Cheng et al. Assessment of gentamicin-induced vestibulotoxicity by click and galvanic vestibular-evoked myogenic potentials: a guinea pig investigation
Shahab Role of Nitrative Stress in Cisplatin Induced Ototoxicity and Synaptic Dysfunction
Kumar Differential Expressions and Functions of P2X1 and P2X4 in the Cochlea
Forge et al. Protection and repair of inner ear sensory cells
Tan Characterisation of Noise-Induced Cochlear Inflammation

Legal Events

Date Code Title Description
FA Abandonment or withdrawal